New Drugs for Heart Failure: What is the Evidence in Older Patients?
Due to associated high hospitalization rate, mortality and costs to healthcare system, heart failure (HF) is a major concern to public health1. In patients with HF, the goals of treatment are to improve clinical status, functional capacity and quality of life (QoL), to prevent hospital admission and to reduce disease-specific and all-cause mortality1-3. Despite substantial improvements obtained with drugs and devices validated in randomized clinical trials (RCTs) over the past thirty years, particularly in the subset with reduced ejection fraction (HFrEF), HF-specific morbidity and mortality are still high2,3. (Source: Jou...
Source: Journal of Cardiac Failure - August 3, 2021 Category: Cardiology Authors: Francesco Orso, Andrea Herbst, Alessandra Pratesi, Francesco Fattirolli, Andrea Ungar, Niccol ò Marchionni, Samuele Baldasseroni Source Type: research

Concurrent Assessment of the CardioMEMS ™ HF System and HeartLogic™ HF Diagnostic: A Retrospective Case Series
Patients with heart failure have a high chance of dying or being admitted to the hospital even though there are excellent medications and medical devices available. Remote patient monitoring for heart failure allows for improvement in medication management, which makes going to the emergency room or hospital less likely. Two commonly used remote patient monitoring devices (e.g. CardioMEMS and HeartLogic) are implanted into the body in different ways, but appear to work in similar ways to keep patients with heart failure out of the hospital. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - August 2, 2021 Category: Cardiology Authors: Jeffrey L. Chilcote, Robert P. Summers, Dev G. Vaz, Regina Barber, Ramesh Wariar, Jason L. Guichard Source Type: research

Dynamics of left ventricular myocardial work in patients hospitalized for acute heart failure
. Left ventricular ejection fraction is the most commonly used measure describing pumping efficiency, but it is heavily dependent on loading conditions and therefore not well suited to study pathophysiologic changes. The novel concept of echocardiography-derived myocardial work (MyW) overcomes this disadvantage as it is based on left ventricular (LV) pressure-strain loops. We tracked the in-hospital changes of indices of MyW in patients admitted for acute heart failure (AHF) in relation to their recompensation status and explored the prognostic utility of MyW indices (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 28, 2021 Category: Cardiology Authors: Floran Sahiti, Caroline Morbach, Carsten Henneges, Ulrich Stefenelli, Nina Scholz, Vladimir Cejka, Judith Albert, Peter U Heuschmann, Georg Ertl, Stefan Frantz, Christiane E. Angermann, Stefan St örk Source Type: research

Fatigue in Persons with Heart Failure: A Systematic Literature Review and Meta-Synthesis Using the Biopsychosocial Model of Health
People living with heart failure often experience fatigue. Fatigue is distressing and can make living life and taking care of yourself difficult. In this article, we reviewed the current research on fatigue in heart failure. We were looking to understand fatigue and what new research is needed to help people with fatigue feel better. We found that in people with heart failure 1) we don't fully understand the physical causes of fatigue, 2) people with depression are more likely to have fatigue, 3) social support helps manage fatigue, and 4) we need more research on interventions to help reduce fatigue. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 27, 2021 Category: Cardiology Authors: Noelle V. Pavlovic, Nisha A. Gilotra, Christopher S. Lee, Chiadi Ndumele, Dimitra Mammos, Cheryl Dennison Himmelfarb, Martha Abshire Saylor Source Type: research

Alternans of the pulse is rarely an alternans of prognosis
“Alternation of the pulse….It is the faint cry of an anguished and fast failing muscle, which, when it comes, all should strain to hear, for it is not long repeated. A few months, a few years at most, and the end comes.”-Lewis 1925 (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 26, 2021 Category: Cardiology Authors: Faris G. Araj, Pradeep P.A. Mammen Source Type: research

We don't talk to patients about their prognosis, but is any of this surprising?
The Surprise Question – “would you be surprised if this person were to die within the next 12 months?” is a prompt to consider advanced care planning and referral to palliative care. Prognosis remains a major driver of such decisions and so the ability of this simple question to identify those within the last year of life has been explored in a number of chronic diseases including heart failure. Despite being able to reliably identify nearly all patients within the last year of life, whilst also accurately identifying those unlikely to die, by asking whether death is possible (rather than probable) only a...
Source: Journal of Cardiac Failure - July 26, 2021 Category: Cardiology Authors: Sam Straw, Melanie McGinlay, John Gierula, Klaus K Witte Source Type: research

Quantifying the Impact of Atrial Fibrillation on HF-Related Patient-Reported Outcomes in the Utah mEVAL Program
Atrial fibrillation frequently complicates HF, and each is associated with lower overall HRQoL. We aimed to quantify the incremental burden of AF on the health-related quality of life of HF patients in clinical practice. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 26, 2021 Category: Cardiology Authors: Benjamin A. Steinberg, Mingyuan Zhang, Jason Bensch, Ann Lyons, T. Jared Bunch, Jonathan P. Piccini, Alfonso Siu, John A. Spertus, Josef Stehlik, Peter Wohlfahrt, Tom Greene, Rachel Hess, James C. Fang Source Type: research

Rituximab for the Treatment of Refractory Cardiac Sarcoidosis –A Single Center Experience
Cardiac involvement is one of the leading causes of death related to sarcoidosis [1]. However, information regarding effective management is limited and the consequences of cardiac sarcoidosis (CS) can be devastating, with these individuals often progressing to the requirement of cardiac transplantation [1]. Research thus far into this rare, but increasingly prevalent (20-fold increase in annual detection along the past 25 years) [1], disease is limited and currently has not allowed for generation of an evidence-based algorithm for treatment [2]. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 24, 2021 Category: Cardiology Authors: Mohamed Elwazir, Megan L. Krause, John P. Bois, Georgios Christopoulos, Ayse T. Kendi, Jr. Leslie T. Cooper, Hayan Jouni, Omar F. AbouEzzeddine, Panithaya Chareonthaitawee, Mohamed Abdel Shafee, Shreyasee Amin Source Type: research

Mid- to late-life inflammation and risk of cardiac dysfunction, HFpEF, and HFrEF in late-life
In this manuscript we demonstrate that in a large population of community-based adults, increased inflammation, based on levels of hsCRP, through mid and late life increases an individual's risk of developing heart failure. In addition, increased inflammation is associated with impaired cardiac structure and function in late-life. Importantly, this risk is largely driven by common health problems, including obesity, high-blood pressure, and chronic kidney disease. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 24, 2021 Category: Cardiology Authors: Aaron J. Cohen, Kanako Teramoto, Brian Claggett, Leo Buckley PharmD, Scott Solomon, Christie Ballantyne, Elizabeth Selvin, Amil M. Shah Source Type: research

HCV Positive Allograft Use in Heart Transplant is Associated With Increased Access to Overdose Donors and Reduced Waitlist Mortality Without Compromising Outcomes
Recent advances in Hepatitis C virus treatment have made the disease curable, and previously discarded hearts from Hepatitis C-positive donors are now able to be transplanted. Evaluating organ use on a regional scale, our study found that transplanting hearts from Hepatitis C-positive donors improved access to an increasingly prevalent population of potential donors dying of drug overdose who would otherwise be suitable donors. This has ultimately translated to less patients dying while awaiting an organ, while patients transplanted with Hepatitis C-positive hearts have shown similar 1-year survival compared to those recei...
Source: Journal of Cardiac Failure - July 24, 2021 Category: Cardiology Authors: Peter J Altshuler, Mark R Helmers, Alexis R Schiazza, Robin Hu, Jason J Han, D Alan Herbst, Amit Iyengar, Pavan Atluri Source Type: research

The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure
Type 2 diabetes (T2D) is an established risk factor for ischemic cardiovascular disease (CVD) and heart failure (HF).(1) The risks of ischemic CVD and HF are increased with albuminuria and/or impaired kidney function. Although in recent decades cardiovascular outcomes have improved for adults with or without T2D, reducing the burden associated with HF by treating classical cardiovascular risk factors has proven to be difficult and thus remains a major public health priority.(2) Accordingly, the introduction of sodium-glucose cotransporter (SGLT) 2 inhibitors offers promise to mitigate cardiorenal disease in people with or ...
Source: Journal of Cardiac Failure - July 17, 2021 Category: Cardiology Authors: Petter Bjornstad, Peter J. Greasley, David C. Wheeler, Glenn M. Chertow, Anna Maria Langkilde, Hiddo J.L. Heerspink, Dani ël H. van Raalte Source Type: research

Prognostic Role of Cardiopulmonary Exercise Testing in Wild Type Transthyretin Amyloid Cardiomyopathy Patients Treated with Tafamidis
The wild type transthyretin amyloid cardiomyopathy (wtATTR) is associated with significant morbidity and mortality with variable median survival around 2-6 years.(1) Recently, Tafamidis received FDA approval for use in ATTR-CM patients after ATTR-ACT randomized controlled trial showing improvement in quality of life and mortality benefit.(2) (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 16, 2021 Category: Cardiology Authors: Tarun Dalia, Prakash Acharya, Wan-Chi Chan, Andrew J. Sauer, Robert Weidling, John Fritzlen, Amandeep Goyal, Dana Miller, Elaine Knipper, Charles B. Porter, Zubair Shah Source Type: research

Incorporating Cardio-Obstetrics into Advanced Heart Failure Training
I recently took care of a young woman in her thirties in my fellows ’ clinic with a newly diagnosed non-ischemic cardiomyopathy with mild dilation and a left ventricular ejection fraction (LVEF) of 20%. She had presented in the middle of the COVID-19 pandemic with decompensated heart failure of unclear etiology. She had three young and healthy children at home, wi th her last pregnancy a few years earlier. She tolerated her prior pregnancies well with the exception of gestational hypertension that evolved into chronic hypertension. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 15, 2021 Category: Cardiology Authors: Ersilia M. DeFilippis Source Type: research

Pericardial Adipose Tissue Volume and Left Ventricular Assist Device-Associated Outcomes
This study aimed to evaluate the associations between PAT and LVAD-associated outcomes. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 15, 2021 Category: Cardiology Authors: Vishal N. Rao, Mary Jo Obeid, Francesca Rigiroli, Stuart D. Russell, Chetan B. Patel, Jeroen Molinger, Rajan T. Gupta, Richa Agarwal, Marat Fudim Tags: Brief Report Source Type: research

Right Heart Dysfunction and Readmission Risk across Left Ventricular Ejection Fraction Status in Patients with Acute Heart Failure
Right heart dysfunction (RHD) parameters, such as pulmonary hypertension (PH), right ventricular dysfunction (RVD), or tricuspid regurgitation (TR), are highly prevalent and increasingly important in heart failure (HF), especially in patients with HF with preserved ejection fraction (HFpEF), in whom PH-RVD has emerged as a specific clinical phenotype. 1-5 Overall, parameters of RHD have been associated withadverse clinical outcomes.3-9 Our group recently proposed an echocardiographic-derived staging system of RHD for risk stratification in HFpEF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 14, 2021 Category: Cardiology Authors: Enrique Santas, Gema Mi ñana, Patricia Palau, Rafael de la Espriella, Miguel Lorenzo, Gonzalo Núñez, Juan Sanchis, Francisco Javier Chorro, Antoni Bayes-Genís, Julio Núñez Source Type: research

Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry
. In the VICTORIA trial, vericiguat reduced the risk of cardiovascular mortality and heart failure (HF) hospitalization among patients with heart failure with reduced ejection fraction (HFrEF) and a recent worsening heart failure event (WHFE). The representativeness of VICTORIA population to patients with WHFE in clinical practice is unknown. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 13, 2021 Category: Cardiology Authors: Javed Butler, Laurence M. Djatche, Dominik Lautsch, Lingfeng Yang, Mahesh J. Patel, Robert J. Mentz Source Type: research

Use of Outpatient Intravenous Calcitropes for Heart Failure in the United States
Outpatient calcitrope infusions —i.e., cardiac inotropes milrinone and dobutamine—are often used for bridge-to-transplantation and palliation in advanced heart failure, but few data exist about real world use of these agents. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 12, 2021 Category: Cardiology Authors: Stephen S. Gottlieb, Mitchell A. Psotka, Nihar Desai, JoAnn Lindenfeld, Pierantonio Russo, Larry A. Allen Tags: Brief Report Source Type: research

Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review
“For many reasons [sarcoidosis] attracts attention and presents feature of great interest. It can no longer be considered a rarity.” -W.T. Longcope (Sarcoidosis: The Frank Billings Lecture; 1941) (1) (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 11, 2021 Category: Cardiology Authors: Nisha A. Gilotra, Jan M. Griffin, Noelle Pavlovic, Brian A. Houston, Jessica Chasler, Colleen Goetz, Jonathan Chrispin, Michelle Sharp, Edward K Kasper, Edward S Chen, Ron Blankstein, Leslie T. Cooper, Emer Joyce, Farooq H. Sheikh Tags: Review Article Source Type: research

Biomarker Testing Considerations in the Evaluation and Management of Patients with Heart Failure: Perspectives from the International Federation of Clinical Chemistry and Laboratory Medicine Committee
The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Clinical Applications of Cardiac Bio-Markers (C-CB) agree on the objective evidence that laboratory biomarkers can provide in the diagnosis of HF and support natriuretic peptides (NP, with BNP and NT-proBNP predominantly available from clinical laboratories) as the most well documented and suitable biomarkers in this regard. We also believe it is important to highlight analytical issues that may affect the clinical interpretation of cardiac biomarkers, including the NPs. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 10, 2021 Category: Cardiology Authors: Peter A. Kavsak, Carolyn S.P. Lam, Amy K. Saenger, Kristin Moberg Aakre, Richard Body, Ola Hammarsten, Paul Collinson, Jordi Ord óñez-Llanos, Torbjørn Omland, Allan S. Jaffe, Fred S. Apple Tags: Perspective Source Type: research

The International Endomyocardial Biopsy Position Paper: A Basis for Integration Into Modern Clinical Practice
Recent years have seen an increase in global, multisociety, consensus-driven guidelines and position papers. These initiatives are a particularly important mechanism of providing a practical and broadly credible approach to common problems that have defied common description and to uncommon scenarios where a large heterogeneity of clinical practice occurs, even in highly specialized, tertiary care settings. The recently published Universal Definition of Heart Failure is a prime example of the former condition,1 whereas the Position Statement of Endomyocardial Biopsy (EMB) published in this issue of the Journal is a corresp...
Source: Journal of Cardiac Failure - July 6, 2021 Category: Cardiology Authors: JONATHAN G. HOWLETT, MARIA G. CRESPO-LEIRO Source Type: research

The International EMB Position Paper: A basis for integration into modern clinical  practice
Recent years have seen the increase in global, multi-society consensus driven Guidelines and Position Papers. These initiatives are a particularly important mechanism to provide a practical and broadly credible approach to common problems which have defied common description, and to uncommon scenarios where a large heterogeneity of clinical practice occurs even in highly specialized, tertiary care settings. The recently published Universal Definition of Heart Failure is a prime example of the former condition1, while the Position Statement of Endomyocardial Biopsy (EMB) published in this issue of the Journal is a correspon...
Source: Journal of Cardiac Failure - July 6, 2021 Category: Cardiology Authors: Jonathan G. Howlett, Maria G. Crespo-Leiro Source Type: research

The Traditional Endomyocardial Biopsy: Opportunities to Rethink its Role as the Gold Standard
The evolution in device optimization and technique modification to the endomyocardial biopsy (EMB) procedure over many decades has resulted in a relatively easy, straightforward, safe, and effective tool for pathological evaluation. (1-2) Early techniques obtaining myocardial biopsies - including percutaneous needle biopsy of the left ventricle, catheter needle biopsy of the interventricular septum, and open thoracotomy - are now simplified to percutaneous biopsies via the right internal jugular vein to the right ventricle under local anesthesia. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 6, 2021 Category: Cardiology Authors: Amit Alam, Jane E. Wilcox, Shelley A. Hall Source Type: research

Cultivating Interest in Heart Failure Careers: Can We Reverse the Current Trend?
It is an exciting time to be a heart failure (HF) physician. After decades of stagnation in the development of effective treatments for HF, we are now enjoying a surge in new medical therapies, greater insights into pathophysiology, and extraordinary innovation in percutaneous and surgical interventions. However, simultaneously, the number of individuals living with and dying from HF continues to grow, with widening racial disparities in HF-related deaths. In this landscape, the growth of a highly skilled, diverse, and agile advanced HF and transplant cardiology (AHFTC) workforce is essential. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 1, 2021 Category: Cardiology Authors: Sarah Chuzi, Nosheen Reza Source Type: research

Iron Deficiency as a Potential Modulator of Subclinical Deficiencies in Cardiac Performance and Exercise Capacity
   (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 1, 2021 Category: Cardiology Authors: Aly Elezaby, Victoria N. Parikh, Matthew Nayor Tags: Editorial Comment Source Type: research

Editorial Board
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 1, 2021 Category: Cardiology Source Type: research

Table of Contents
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 1, 2021 Category: Cardiology Source Type: research

Masthead
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 1, 2021 Category: Cardiology Source Type: research

Picking up the Pieces of a Shattered Dream
It was May 2020, and less than a week had passed since the murder of George Floyd. I read the messages that close friends posted on social media of their tearfulness, difficulty sleeping, and trouble concentrating at work. A few friends and family called to ask why their blood pressure had been running so high. As a physician, I quickly recognized the association between stress and cardiovascular disease. My understanding of this pathophysiology, however, did not make it any easier to witness my loved ones suffer, or to personally suffer, the psychosomatic effects of being Black in America. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 1, 2021 Category: Cardiology Authors: Alanna A. Morris Tags: Editor's Page: We've Been Thinking … Source Type: research

nAddendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2 —evidence base and standardized methods of imaging
There are two primary reasons for an addendum. The first is that the document reviewer list is being updated to include Dr. Richard Cheng and Dr. Roy John, who have critically reviewed the document, but were inadvertently not listed as reviewers. In addition, since the publication of this document and introduction of approved therapies for transthyretin cardiac amyloidosis (ATTR-CA), the clinical use of bone tracer cardiac scintigraphy has been extended to populations with lower prevalence of ATTR-CA. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - July 1, 2021 Category: Cardiology Authors: Sharmila Dorbala, Yukio Ando, Sabahat Bokhari, Angela Dispenzieri, Rodney H. Falk, Victor A. Ferrari, Marianna Fontana, Olivier Gheysens, Julian D. Gillmore, Andor W.J.M. Glaudemans, Mazen A. Hanna, Bouke P.C. Hazenberg, Arnt V. Kristen, Raymond Y. Kwong, Source Type: research

Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial
Despite significant advances in the medical and device-based management of patients with heart failure (HF) with reduced ejection fraction (HFrEF), risk for adverse outcomes remains high in these patients, particularly after a recent decompensation.1,2 Risk models may inform the assessment of prognosis, planning of new trials, and clinical management decisions and treatment selection, particularly when there is evidence of a differential benefit of therapies aligned with baseline risk3 or clinical phenotype (ie, baseline characteristics). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 30, 2021 Category: Cardiology Authors: Robert J. Mentz, Hillary Mulder, Arend Mosterd, Nancy K. Sweitzer, Michele senni, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Burkert Pieske, Piotr Ponikowski, Adriaan A. Voors, Kevin J. Anstrom, Paul W. Armstrong, Christopher M. O'connor, Adrian Source Type: research

Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States
Maintaining a steady medication supply during a public health crisis is a major health priority. We leveraged a large U.S. pharmacy-claims database to understand the use of evidence-based therapies in heart failure (HF) care during the coronavirus disease-2019 (COVID-19) pandemic. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 29, 2021 Category: Cardiology Authors: Muthiah Vaduganathan, Diane Li, Jeroen Van Meijgaard, Haider J. Warraich Tags: Brief Report Source Type: research

US Nationwide Prescription Fill Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic
Maintaining a steady medication supply during a public health crisis is a major health priority. We leveraged a large US pharmacy claims database to understand utilization of evidence-based therapies used in heart failure (HF) care during the coronavirus disease-2019 (COVID-19) pandemic. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 29, 2021 Category: Cardiology Authors: Muthiah Vaduganathan, Diane Li, Jeroen van Meijgaard, Haider J. Warraich Source Type: research

The Impact of Depression on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial
The syndrome of heart failure (HF) is quite often accompanied by a burden of comorbidities [1]. Among these, mental illness is often overlooked [2]. For example, studies show that depression is prevalent in up to 25% of all patients with HF and independently predicts adverse clinical outcomes [2]. It is suspected that effective and comprehensive care of HF requires a focus on confronting psychiatric comorbidities along with treatment of the cardiac disease. However, it remains unknown as to whether depression influences the medical treatment of HF or whether it interferes with the efficacy medical therapies. (Source: Journ...
Source: Journal of Cardiac Failure - June 21, 2021 Category: Cardiology Authors: Fouad Chouairi, Michael A. Fuery, Clancy W. Mullan, Cesar Caraballo, Sounok Sen, Christopher Maulion, Samuel T. Wilkinson, Toral Surti, Megan McCullough, P. Elliott Miller, Justin Pacor, Eric S Leifer, G. Michael Felker, Eric J. Velazquez, Mona Fiuzat, Ch Source Type: research

Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid Sparing Agent
This study describes a cohort of patients undergoing treatment with mycophenolate mofetil for cardiac sarcoidosis. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 21, 2021 Category: Cardiology Authors: Jan M. Griffin, Jessica Chasler, Alison L. Wand, David R. Okada, J. Nikolhaus Smith, Elie Saad, Hari Tandri, Jonathan Chrispin, Michelle Sharp, Edward K. Kasper, Edward S. Chen, Nisha A. Gilotra Source Type: research

Self-care Management Intervention in Heart Failure (SMART-HF): A Multicenter Randomized Controlled Trial
Self-care behavior is important in avoiding hospitalization for patients with heart failure (HF) and refers to those activities performed with the intention of improving or restoring health and well-being, as well as treating or preventing disease. The purpose was to study the effects of a home-based mobile device on self-care behavior and hospitalizations in a representative HF-population. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 20, 2021 Category: Cardiology Authors: DANIEL Sahlin, BABAK REZANEZAD, MARIE-LOUISE EDVINSSON, ERASUMS BACHUS, OLLE MELANDER, SOFIA GERWARD Source Type: research

Selfcare Management Intervention in Heart Failure (SMART-HF) -A multicentre randomized controlled trial
Self-care behaviour is important in avoiding hospitalization for patients with heart failure (HF) and refers to those activities performed with the intention of improving or restoring health and well-being, as well as treating or preventing disease. The purpose was to study the effects of a home-based mobile device on self-care behaviour and hospitalizations in a representative HF-population. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 20, 2021 Category: Cardiology Authors: D. Sahlin, B. Rezanezad, M.L. Edvinsson, E. Bachus, O. Melander, S. Gerward Source Type: research

Presence of intracardiac thrombus at the time of left ventricular assist device implantation is associated with increased risk of stroke and death
Left ventricular assist device (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 20, 2021 Category: Cardiology Authors: Claudio A. Bravo, Justin A. Fried, Joshua Z. Willey, Azka Javaid, Giulio M. Mondellini, Lorenzo Braghieri, Heidi Lumish, Veli K. Topkara, Yuji Kaku, Lucas Witer, Hiroo Takayama, Koji Takeda, Gabriel Sayer, Nir Uriel, Ryan T. Demmer, Yoshifumi Naka, Melana Source Type: research

Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices
Studies on the optimal pharmacological heart failure (HF) therapy after left ventricular assist device (LVAD)b implantation are scarce. From a pathophysiological perspective, neurohormonal blockade offers additional benefits to mechanical unloading. A small-scale study showed a beneficial effect of pharmacological HF therapy on the structure and function of the myocardium after LVAD implantation.(1) The burden of the common and serious long-term complications associated with heart failure progression (such as right heart failure (2) and ventricular arrhythmia (3)) call for an evaluation of the potential positive effects of...
Source: Journal of Cardiac Failure - June 19, 2021 Category: Cardiology Authors: Jessica Kristin Schnettler, Luise Roehrich, Isabell Anna Just, Panagiotis Pergantis, Julia Stein, Marcus Mueller, Johanna Mulzer, Jan Knierim, Volkmar Falk, Evgenij Potapov, Felix Schoenrath Source Type: research

Chronic Intravenous Inotropic Support as Palliative Therapy and Bridge Therapy for Patients With Advanced Heart Failure: A Single-Center Experience
This study analyzed the clinical trajectory of patients with advanced heart failure who were on home CIIS. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 18, 2021 Category: Cardiology Authors: Anirudh Rao, Kelley M. Anderson, Selma Mohammed, Mark Hofmeyer, Sherry S. Gholami, Farooq H. Sheikh, Maria E. Rodrigo, Nancy A. Crowell, Hasan Javed, Shantal Gupta, Said Hajouli, Diana E. Stewart, Ahmad Hamad, Samer S. Najjar, Hunter Groninger Source Type: research

Combination Biomarkers for Risk Stratification in Patients with Chronic Heart Failure Biomarkers Prognostication in HF
Heart failure (HF) is a complex clinical syndrome that leads to a malfunctioning cardiac pump, preventing adequate perfusion to internal organs and peripheral tissues1. The prevalence of HF is approximately 6.2 million patients in the United States and 23 million worldwide, with approximately 50% of the cases being HF with reduced ejection fraction (HFrEF). Fortunately, the survival after HF has been improving, but the 5-year mortality is still close to 50%1. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 18, 2021 Category: Cardiology Authors: Zekun Feng, Olumuyiwa P. Akinrimisi, Jeffrey A. Gornbein, Quynh A. Truong, Saumya Das, Jagmeet P. Singh, Olujimi Ajijola Source Type: research

Chronic Intravenous Inotropic Support as Palliative Therapy and Bridge Therapy for Advanced Heart Failure Patients: A Single-Center Experience
This study analyzed the clinical trajectory of patients with advanced heart failure (HF) on home CIIS. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 18, 2021 Category: Cardiology Authors: Anirudh Rao, Kelley M Anderson, Selma Mohammed, Mark Hofmeyer, Sherry S Gholami, Farooq H Sheikh, Maria E Rodrigo, Nancy A Crowell, Hasan Javed, Shantal Gupta, Said Hajouli, Diana E Stewart, Ahmad Hamad, Samer S Najjar, Hunter Groninger Source Type: research

“I've Had a Good Run”
Patients with heart failure (HF) who we take care of over many years don't exactly become "friends," but mutual bonds do form that transcend the strict doctor/patient relationship. They become more than simply "patients." We get to know family members, likes and dislikes, anecdotes from their lives, sometimes political stances, and more. And although they generally know a lot less about us than we do about them, they still often find out about major life events like births of kids and grandkids, marriages, and more, as well as random facts we might share. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 17, 2021 Category: Cardiology Authors: MARK E. DUNLAP Source Type: research

"I've had a good run"
Patients with HF who we take care of over many years don't exactly become "friends", but mutual bonds do form that transcend the strict doctor/patient relationship. They become more than simply "patients". We get to know family members, likes and dislikes, anecdotes from their lives, sometimes political stances, and more. And while they generally know a lot less about us than we do about them, they still often find out about major life events like births of kids and grand-kids, marriages, and more, as well as random facts we might share. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 17, 2021 Category: Cardiology Authors: Mark Dunlap Source Type: research

Older Patients with Acute Decompensated Heart Failure Who Live Alone: An Analysis from the REHAB-HF Trial
We assessed the prevalence and clinical characteristics of patients with acute decompensated heart failure (ADHF) who live alone and how they were different from patients who lived with someone else. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 17, 2021 Category: Cardiology Authors: Haider J. Warraich, Dalane W. Kitzman, M. Benjamin Nelson, Robert J. Mentz, Paul B. Rosenberg, Yair Lev, David J. Whellan Source Type: research

Practices of Referring Patients to Advanced Heart Failure Centers
Despite major advances in treatment, heart failure (HF) remains a disease that involves high rates of morbidity and adversely impacts quality of life and survival. Medical and device therapies for HF have improved outcomes; however, the use of advanced therapies, such as left ventricular assist device (LVAD) support and orthotopic heart transplant (OHT) remains low.1 –6 Advanced heart failure (AHF) management is multifaceted, requiring the coordinated care of a specialized, multidisciplinary team. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 15, 2021 Category: Cardiology Authors: Jared J. Herr, Ashwin Ravichandran, Farooq H. Sheikh, Anuradha Lala, Christopher V. Chien, Stephanie Hsiao, Ajay Srivastava, Dawn Pedrotty, Jennifer Nowaczyk, Shannon Tompkins, Sara Ahmed, Fei Xiang, Stephen Forest, Michael Z. Tong, Benjamin D'souza, IDEA Source Type: research

Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action from the HELP Trial
Levosimendan is a K+-ATPase activator, cardiac myofilament Ca2+-sensitizer, and phosphodiesterase inhibitor with positive inotropic effects and vasodilatory properties in the pulmonary and systemic circulation, all of which are potential therapeutic targets for patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) [1]. In the recent multicenter, double-blind, placebo-controlled Hemodynamic Evaluation of Levosimendan in Patients with HFpEF (HELP) study, a weekly infusion of levosimendan decreased pulmonary capillary wedge pressure (PCWP) and central venous pressure (CVP) and was ...
Source: Journal of Cardiac Failure - June 15, 2021 Category: Cardiology Authors: Michael I. Brener, Nadira B. Hamid, Kenji Sunagawa, Barry A. Borlaug, Sanjiv J. Shah, Stuart Rich, Daniel Burkhoff Tags: Brief Report Source Type: research

Patient Referral Practices to Advanced Heart Failure Centers
Despite major advances in treatment, heart failure (HF) remains a highly morbid disease adversely impacting quality of life (QOL) and survival. Medical and device therapies for HF have improved outcomes, however penetration of advanced therapies such as left ventricular assist device (LVAD) support and orthotopic heart transplant (OHT) remains low [1-6]. Advanced heart failure (AHF) management is multifaceted, requiring the coordinated care of a specialized, multidisciplinary team [6-9]. The ability to offer OHT and/or LVAD depends on many factors including timeliness of referrals; however, the pattern of referrals remains...
Source: Journal of Cardiac Failure - June 15, 2021 Category: Cardiology Authors: Jared J Herr, Ashwin Ravichandran, Farooq H. Sheikh, Anuradha Lala, Christopher V. Chien, Stephanie Hsiao, Ajay Srivastava, Dawn Pedrotty, Jennifer Nowaczyk, Shannon Tompkins, Sara Ahmed, Fei Xiang, Stephen Forest, Michael Z. Tong, Benjamin D'Souza, IDEAL Source Type: research

Left Ventricular Assist Devices at the Crossroad of Innovation in Advanced Heart Failure
Two decades ago, the nascent field of left ventricular assist devices (LVADs) encountered a paradigm shift. The older, bulkier devices which provided suitable circulatory support for short-term life prolongation in severe heart failure were plagued by poor device durability and a high burden of morbidity. Bioengineers developed continuous flow devices which were small in profile, had few moving parts and, as a consequence, exhibited greater durability. Clinical trials demonstrated a marked improvement in survival compared with older generation pumps, and patients approaching refractoriness to neurohormonal therapy with adv...
Source: Journal of Cardiac Failure - June 14, 2021 Category: Cardiology Authors: Mandeep R. Mehra, Finn Gustafsson Source Type: research

Racial and Ethnic Disparities Persist in the Current Era of Pediatric Heart Transplantation
: Older studies demonstrated that children in the U.S. from racial and ethnic minorities have inferior waitlist and post-heart transplant (HT) outcomes. Whether these disparities still exist in the contemporary era of increased ventricular assist device utilization remains unknown. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 14, 2021 Category: Cardiology Authors: Shahnawaz Amdani, Salima A. Bhimani, Gerard Boyle, Wei Liu, Sarah Worley, Elizabeth Saarel, Eileen Hsich Source Type: research

Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan
B-type natriuretic peptide (BNP) immunoassays (BNPia) do not differentiate active and inactive forms. Inactive NT-proBNP is used to track heart failure (HF) during treatment with sacubitril/valsartan, which inhibits BNP degradation. Mass spectrometry (MS) may better assess effects of HF treatment on biologically active BNP1-32. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 13, 2021 Category: Cardiology Authors: Erica M. Dillon, Shouzuo D. Wei, Deepak K. Gupta, Hui Nian, Brooks S. Rodibaugh, Katherine N. Bachmann, Allen J. Naftilan, Lynne W. Stevenson, Nancy J. Brown Source Type: research